Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Hemlibra (Emicizumab): Economic Review Report

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Number:
OB0005-000

This report aims to:

  • Assess the cost effectiveness of emicizumab (Hemlibra) used as prophylaxis compared with prophylaxis with bypassing agents (BPA) and on-demand (episodic) use of BPAs, in patients hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
  • Assess, from the Canadian health ministry perspective, the budgetary impact of reimbursing emicizumab, over a three-year period, in patients hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.

Files

Hemlibra (Emicizumab): Economic Review Report Technology Review September 11, 2019 View PDF
Last Updated : September 11, 2019